#198 SGLT2 Inhibitors and Diabetics: Does sugar in the pee protect thee?
CLINICAL QUESTION
In patients with type 2 diabetes, do sodium-glucose co-transporter 2 (SGLT2) inhibitors affect mortality or cardiovascular disease (CVD)?
BOTTOM LINE
In diabetic patients at high-risk for CVD, empagliflozin reduces mortality for 1 in 39 patients at ~3 years (compared to placebo), while canagliflozin and empagliflozin both reduce CVD death, non-fatal myocardial infarction (MI), and stroke for ~1 in 60 patients. Both medications increased genital infections for ~1 in 6-22 and canagliflozin increased volume depletion (1 in 14-38) and amputations (1 in 96). Cost may limit use.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Two placebo-controlled, industry-funded, Randomized Controlled Trials (RCTs) of mostly males, long-standing type 2 diabetics in their 60s with A1cs ~8.1,2 Patients with GFR <30 ml/min were excluded.
- Empagliflozin 10 mg or 25 mg daily:1 7,020 patients with CVD mostly also on metformin, anti-hypertensives, statins, and ASA. At 3.1 years, empagliflozin significantly effected:
- CVD death, non-fatal MI, or stroke: 10.5% (empagliflozin) versus 12.1% (placebo), Number Needed to Treat (NNT)=63.
- Mortality: 5.7% versus 8.3%, NNT=39.
- Genital infections: 6.4% versus 1.8% (placebo), Number Needed to Harm (NNH)=22.
- No increase in fractures or volume depletion.
- Meta-analysis (57 RCTs, six regulatory submissions) had similar findings.3
- Canagliflozin 100 mg or 300 mg daily:2 10,142 patients from two different studies (with different enrollment and study lengths), with either CVD or ≥2 CVD risk factors. Concomitant medications unknown. Statistically significant outcomes from combined studies over 3.6 years, except where indicated:
- CVD death, non-fatal MI, or stroke: 2.7% (canagliflozin) versus 3.2% per year; NNT~61 over 3.6 years.
- Mortality: 1.7% (canagliflozin) versus 2% per year (approaches statistical significance).
- Genital infections: NNH=6 (female) to 12 (male).
- ‘Volume depletion’ (dry mouth/polydipsia to orthostatic hypotension/syncope): NNH=14-38.
- Amputation: NNH=96.
- Fractures: NNH=286.
- Neither RCT demonstrated significant increase in urinary tract infection, acute kidney injury, hypoglycemia, or diabetic ketoacidosis.
- Empagliflozin 10 mg or 25 mg daily:1 7,020 patients with CVD mostly also on metformin, anti-hypertensives, statins, and ASA. At 3.1 years, empagliflozin significantly effected:
- ~50% of diabetics die from CVD.4
- Both medications lower systolic blood pressure ~3-4 mmHg, A1c ~0.5%, and weight ~2kg.1,2
- CADTH recommends empagliflozin (after Metformin) for diabetics with CVD.5
- Post marketing warnings: Acute kidney injury with canagliflozin or dapagliflozin6 and fractures7 and amputations8 with canagliflozin.
- Cost ~$90 per month.9
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
